Foreign media: According to Dealogic data, by 2025, the funding in China's healthcare sector has reached a record high of 10.6 billion US dollars, exceeding the total of 2022 to 2024.
This growth is mainly driven by strong global investor demand and the booming biotechnology industry, especially in areas targeting life-threatening diseases such as cardiovascular diseases and cancer.
Outbound licensing, efficiency improvement, and cost control are driving China's biotechnology industry to become a highlight in the market.
Original article: www.toutiao.com/article/1842866396232771/
Statement: This article represents the views of the author himself.